SHAREHOLDER ALERT: SPRO VRCA UL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / July 25, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Spero Therapeutics, Inc. SPRO

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=30177&wire=1
Lead Plaintiff Deadline: July 25, 2022
Class Period: May 6, 2021 - May 2, 2022

Allegations against SPRO include that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Verrica Pharmaceuticals, Inc. VRCA

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=30177&wire=1
Lead Plaintiff Deadline: August 5, 2022
Class Period: May 28, 2021 - May 24, 2022

Allegations against VRCA include that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Unilever PLC UL

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/unilever-plc-loss-submission-form?prid=30177&wire=1
Lead Plaintiff Deadline: August 15, 2022
This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.

Allegations against UL include that: a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in "Occupied Palestinian Territory" ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE : The Law Offices of Vincent Wong